These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34197949)
1. A review of the racial heterogeneity of breast cancer stem cells. Gyan E; Owiredu WKBA; Fondjo LA; Jackson AM; Green AR; Rahman GA Gene; 2021 Sep; 796-797():145805. PubMed ID: 34197949 [TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cells: A fallow research ground in Africa. Gyan E; Fondjo LA; Owiredu W; Jackson A; Green A Pathol Res Pract; 2020 Oct; 216(10):153118. PubMed ID: 32853953 [No Abstract] [Full Text] [Related]
3. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population. Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998 [TBL] [Abstract][Full Text] [Related]
4. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075 [TBL] [Abstract][Full Text] [Related]
5. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype. Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209 [TBL] [Abstract][Full Text] [Related]
6. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632 [TBL] [Abstract][Full Text] [Related]
7. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Nakshatri H; Srour EF; Badve S Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630 [TBL] [Abstract][Full Text] [Related]
8. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303 [TBL] [Abstract][Full Text] [Related]
9. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Lee HE; Kim JH; Kim YJ; Choi SY; Kim SW; Kang E; Chung IY; Kim IA; Kim EJ; Choi Y; Ryu HS; Park SY Br J Cancer; 2011 May; 104(11):1730-8. PubMed ID: 21559013 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma. Han SA; Jang JH; Won KY; Lim SJ; Song JY Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160 [TBL] [Abstract][Full Text] [Related]
11. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574 [TBL] [Abstract][Full Text] [Related]
12. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics. Shao J; Fan W; Ma B; Wu Y Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965 [TBL] [Abstract][Full Text] [Related]
14. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614 [TBL] [Abstract][Full Text] [Related]
15. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655 [TBL] [Abstract][Full Text] [Related]
16. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116 [TBL] [Abstract][Full Text] [Related]
17. High GD2 expression defines breast cancer cells with enhanced invasiveness. Mansoori M; Roudi R; Abbasi A; Abolhasani M; Abdi Rad I; Shariftabrizi A; Madjd Z Exp Mol Pathol; 2019 Aug; 109():25-35. PubMed ID: 31075227 [TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657 [TBL] [Abstract][Full Text] [Related]
19. Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. Dhumal SN; Choudhari SK; Patankar S; Ghule SS; Jadhav YB; Masne S Head Neck Pathol; 2022 Jun; 16(2):453-465. PubMed ID: 34655409 [TBL] [Abstract][Full Text] [Related]
20. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]